BRILINTA 90 MG AstraZeneca
| Features | |
| Active substance | Ticagrelor |
| Also known as | AZD6140 |
| Blood pressure | Can cause transient increase |
| Chemical name | (1S,2S,3R,5R)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
| Dosage (medical) | Typically 90 mg twice daily |
| Dosage (sports) | Not applicable |
| Effects | Reduces the rate of stent thrombosis in patients who are at risk, decreases myocardial infarction |
| FORM | 56 pills x 90 mg |
| Formula | C23H28F2N6O4S |
| Half-life | Approximately 7 to 8.5 hours |
| Hepatotoxicity | Low risk |
| Lab Test | Not specific, may monitor platelet function tests |
| Main action | Platelet aggregation inhibitor |
| Side effects | Bleeding, dyspnea, headache, cough, hypertension, nausea |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Substance class | Antiplatelet agent |
| Trade name | Brilinta, Brilique, Possia |
| Use in sports | Not typically used in sports |
| Water Retention | None |
| Manufacturer | AstraZeneca |